Introduction {#sec1_1}
============

Nephropathic cystinosis is a severe systemic progressive disease. It involves several organs throughout life. First, the kidneys are affected by proximal tubular dysfunction and Fanconi\'s syndrome. During childhood, there is also frequent hypothyroidism and ocular involvement, leading to photophobia. Renal glomerular damage generally becomes apparent between 2 and 5 years of age and results in end-stage renal disease between 9 and 10 years of age, unless treatment with a cystine-depleting drug, cysteamine, is initiated early in life \[[@B1]\]. Patients without this treatment, besides presenting glomerular damage and chronic renal insufficiency, can also present pancreatic problems, e.g. diabetes mellitus and high levels of amylase, hepatic involvement, gastrointestinal complications, e.g. vomiting or gastric ulcers, muscular wasting and weakness, and various degrees of central nervous system involvement \[[@B1], [@B2]\]. However, although lysosomal cystine accumulation is the hallmark of cystinosis and is regarded as the primary defect due to mutations in the *CTNS* gene, there is great evidence that cystine accumulation itself is not responsible for all abnormalities observed in cystinosis. Several studies have recently demonstrated altered ATP metabolism, increased apoptosis, and cell oxidation. For the most part, these abnormalities were observed using cell models and are not necessarily mutually exclusive \[[@B3]\]. Moreover, an increased number of autophagosomes and autophagic vacuoles have been observed in cystinotic fibroblasts and renal epithelial cells, suggesting that altered autophagy also plays a role in cystinosis \[[@B4]\]. These observations were associated with structural mitochondrial abnormalities and increased production of reactive oxygen species (ROS). Taken together, these findings suggest that cystinosis patients can be more susceptible to oxidative stress, which can contribute to the progression of renal disease in cystinosis patients even when they show a good response to treatment with cysteamine \[[@B5], [@B6]\].

Our aim was to evaluate a marker of oxidative stress in pediatric cystinosis and compare the results obtained in cystinotic children with those observed in healthy normal controls. We also correlated the oxidative stress marker with renal function parameters in these patients. Of note, this is the first documentation of increased oxidative stress in the serum of cystinotic patients.

Patients and Methods {#sec1_2}
====================

Patients {#sec2_1}
--------

The study cohort was selected from cystinosis patients aged \<18 years. Inclusion criteria were parental consent for participation in the study and good adherence to the treatment, including their attendance at the follow-up examinations and clinical evaluations, and no renal replacement therapy. Only patients with chronic kidney disease (CKD) in stage 1--4 (based on KDOQI guidelines \[[@B7]\]) were included.

All patients selected had taken cysteamine at a recommended dosage of 60--90 mg/kg/day \[[@B5]\]. Sample collections to measure the parameters of the study were done at the time when patients were under metabolic and electrolyte control, and free of infections.

Methods {#sec2_2}
-------

The following renal function parameters were evaluated: serum creatinine, BUN and creatinine clearance estimated by the Schwartz formula \[[@B8]\].

Serum levels of thiobarbituric acid-reactive substances (TBARS), which are markers of lipid peroxidation, were determined using the TBARS assay. In brief, 0.2 ml of serum sample was diluted in 0.8 ml of distilled water. Immediately thereafter, 1 ml of 17.5% trichloroacetic acid was added. Following the addition of 1 ml of 0.6% thiobarbituric acid, pH 2, the sample was placed in a boiling water bath for 15 min, after which it was allowed to cool. Subsequently, 1 ml of 70% trichloroacetic acid was added, and the mixture was incubated for 20 min. The sample was then centrifuged for 15 min at 2,000 r.p.m. The optical density of the supernatant was read at 534 nm against a reagent blank using a spectrophotometer. The quantity of TBARS was calculated using a molar extinction coefficient of 1.56 × 10^5^*M*^−1^ cm^−1^.

Serum levels of TBARS (expressed as nmol/ml \[[@B9]\]) were compared between patients and healthy controls, and associations between this parameter and parameters of renal function were assessed.

Statistical Analysis {#sec2_3}
--------------------

Homogenous data are expressed as means ± SD, and non-homogenous data are expressed as medians (interquartile ranges). The independent sample t test was employed to compare serum levels of TBARS between the patients and healthy control children, and Pearson\'s correlation coefficient was used to correlate serum TBARS with renal function parameters. This study was approved by the local ethics committee. Informed consent was obtained from the parents of all children for participation in this study.

Results {#sec1_3}
=======

We selected 20 cystinosis patients (6 females) aged 8.0 ± 3.6 years (mean ± SD) in CKD stage 1--4 with good adherence to the treatment comprising cysteamine. The distribution of the patients according to CKD stage is shown in table [1](#T1){ref-type="table"}. The dosage of cysteamine was 72.06 ± 5.22 mg/kg/day and was divided every 6 h.

Table [2](#T2){ref-type="table"} shows the results found in these cystinosis patients. In the 43 healthy controls aged 7.4 ± 1.1 years (mean ± SD), serum levels of TBARS were 1.60 ± 0.04 nmol/ml (mean ± SD); in cystinosis patients, serum TBARS levels were 4.03 ± 1.02 nmol/ml (mean ± SD). There was no statistical difference between patients and healthy controls regarding age, but there was a significant difference between the plasma TBARS levels between both groups (p \< 0.0001).

To determine the effect of renal function impairment on serum TBARS, we correlated this parameter with serum creatinine, BUN, creatinine clearance estimated by stature and CKD stage. No significant correlations between plasma TBARS and all these parameters were detected (fig. [1](#F1){ref-type="fig"}).

Discussion {#sec1_4}
==========

Nephropathic cystinosis is a severe disease. Although cysteamine treatment improves its prognosis, renal failure is not completely abolished. Gahl et al. \[[@B6]\] emphasized that cysteamine is not 100% effective, even taking all appropriate steps, since some patients present extrarenal complications and renal failure at the age of 20 years. Likewise, Greco et al. \[[@B10]\] have also demonstrated that end-stage renal failure cannot be prevented in most patients but is only postponed to the 2nd or 3rd decade of life; late-onset complications ultimately develop in a substantial proportion of patients. Ergo, nephropathic cystinosis remains a challenge for the treating physician.

Recently, several studies have demonstrated altered ATP metabolism, and increased apoptosis and cell oxidation in cystinosis \[[@B3]\]. In addition, increased autophagy is involved leading to increased ROS production \[[@B4]\]. Most of the studies have been conducted in cell models, but a study assessing oxidative stress in the serum of the patients has not been published to date. Therefore, our aim was to evaluate serum TBARS levels in pediatric cystinosis patients. Using this simple methodology, we observed that plasma TBARS, a biomarker of oxidative stress, was increased in patients with nephropathic cystinosis. The balance between oxidants and antioxidants is considerably distorted in patients with chronic renal insufficiency. Evidence suggests that ROS are not merely the consequence of treatment or progressing disease but also one of the causal agents of chronic renal impairment, and that oxidative stress can occur even in the absence of hemodialysis. Patients with uremia have diminished response to oxidative stress probably due to a decrease in the antioxidant capacity; the mechanisms underlying this decrease, however, remain to be elucidated \[[@B11]\]. However, in this study, we could not correlate TBARS levels with creatinine clearance, CKD stage, serum creatinine or BUN. Therefore, in cystinosis patients oxidative stress could be a result of the intrinsic mechanism of the disease \[[@B3]\]. Oxidative stress results in the formation of highly reactive and unstable lipid hydroperoxides, and decomposition of unstable peroxides derived from polyunsaturated fatty acids results in the formation of malondialdehyde, which is measured by the TBARS assay. However, a drawback of this assay is that there may be other sources of malondialdehyde. Thus, this test is not specific for lipid peroxidation.

The limitations of our study are the small number of patients and the fact that TBARS is not the best oxidative stress marker. Although this is only a pilot study, it is of paramount importance since it is the first report proving that oxidative stress is increased in the serum of patients with cystinosis independent of the state of renal function. Therefore, we intend to assess more specific markers in future studies.

This knowledge may have implications on the treatment of cystinosis patients, since oxidative stress is involved in the progression of renal disease, especially in these patients \[[@B11]\].

![Correlation between plasma TBARS and serum creatinine (**a**, **c**), BUN (**b**) and creatinine clearance estimated by stature \[eGFR (Schwartz formula); **d**\] in nephropathic cystinosis patients. **a** r = −0.04, p = 0.86. **b** r = 0.02, p = 0.93. **c** r = −0.10, p = 0.65. **d** r = 0.17, p = 0.46.](nne-0001-0073-g01){#F1}

###### 

Cystinosis patients (n = 20) according to CKD stage

  ------------- ------------
  CKD stage 1   9 patients
  CKD stage 2   5 patients
  CKD stage 3   5 patients
  CKD stage 4   1 patient
  ------------- ------------

###### 

Parameters measured in the 20 cystinosis patients

  ------------------------------------------- -------------
  Serum creatinine, μmol/l                    
   Median                                     59.5
   Interquartile range                        39.6--93.0
   Geometric mean, log transformed            61.0
  BUN, mmol/l                                 10.3 ± 5.7
  eGFR (Schwartz formula), ml/min/1.73 m^2^   84.0 ± 41.5
  Serum TBARS, nmol/ml                        4.03 ± 1.02
  ------------------------------------------- -------------
